Concepedia

Aaron Weitzman

AW

28

Publications

2.3K

Citations

19

H-Index

1999

Active since

Affiliations

The University of Texas MD Anderson Cancer Center(Current)

Exelixis (United States)

Memorial Sloan Kettering Cancer Center

Massachusetts General Hospital

Institute of Cancer Research

Aaron Weitzman is an author at The University of Texas MD Anderson Cancer Center specializing in medicine, oncology, and pharmacotherapy.

Top concepts

Publications per year

1999–2020

28

Publications

28

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

Hagop M. Kantarjian, Francis J. Giles, Norbert Gattermann et al. · Blood · 2007 · 742 citations · Full text

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

David C. Smith, Matthew R. Smith, Christopher J. Sweeney et al. · Journal of Clinical Oncology · 2012 · 442 citations · Full text

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1

Matthew R. Smith, Johann S. de Bono, Cora N. Sternberg et al. · Journal of Clinical Oncology · 2016 · 244 citations

UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia

Jonathan B. Singer, Yaping Shou, Francis J. Giles et al. · Leukemia · 2007 · 122 citations

, , +3

Phase I/II studies of docetaxel (Taxotere) combined with estramustine in men with hormone-refractory prostate cancer.

Daniel P. Petrylak, Robert B. MacArthur, Jacqueline M. O’Connor et al. · PubMed · 1999 · 93 citations

Rows per page

1–5 of 28